主页 > 医药科学 >
【drug-news】新研究：考来维仑对于接受胰岛素治
"Poor glycemic control is a risk factor for microvascular complications in patients with type 2 diabetes mellitus," write Ronald B. Goldberg, MD, from the University of Miami in Florida, and colleagues. "Achieving glycemic control safely with insulin therapy can be challenging."
Between August 12, 2004, and December 28, 2005, this prospective, 16-week, double-blind, parallel-group study was conducted at 50 sites in the United States and at 1 site in Mexico. Inclusion criteria were type 2 diabetes mellitus inadequately controlled (glycated hemoglobin level, 7.5% - 9.5%) with insulin therapy alone or in combination with oral antidiabetic agents.
Mean age of the participants was 57 years, mean baseline glycated hemoglobin level was 8.3%, and 52% were men. Of 287 participants, 147 were randomly assigned to receive colesevelam hydrochloride 3.75 g/day, and 140 were randomly assigned to receive placebo.
Mean change in glycated hemoglobin level from baseline to week 16 with use of the least-squares method was −0.41% ± 0.07% in the colesevelam group and 0.09% ± 0.07% in the placebo group (treatment difference, −0.50% ± 0.09%; 95% confidence interval, −0.68% to −0.32%; P < .001). Colesevelam therapy was associated with consistent reductions in fasting plasma glucose and fructosamine levels, glycemic-control response rate, and lipid control measures. Compared with the placebo group, the colesevelam group had a 12.8% decrease in low-density lipoprotein cholesterol concentration (P < .001).
Both colesevelam and placebo were generally well tolerated. In the colesevelam and placebo groups, respectively, 30 and 26 participants discontinued the study prematurely, 7 and 9 participants withdrew because of protocol-specified hyperglycemia, and 10 and 4 participants withdrew because of adverse events.
"Colesevelam treatment seems to be safe and effective for improving glycemic control and lipid management in patients with type 2 diabetes mellitus receiving insulin-based therapy, and it may provide a novel treatment for improving dual cardiovascular risk factors," the study authors write. "The use of bile acid sequestrants in the treatment of both hyperglycemia and elevated LDL-C [low-density lipoprotein cholesterol] concentrations thus comprises a novel therapeutic approach for T2DM [type 2 diabetes mellitus]. In the present trial, colesevelam was weight neutral and well tolerated, and the overall results of this study suggest a favorable safety profile in subjects with T2DM who are receiving insulin therapy."
The National Institutes of Health and Daiichi Sankyo supported this study. Daiichi Sankyo employs 2 study authors and has various financial relationships with 2 additional authors, who also have disclosed various financial relationships with Eli Lilly, Takeda, Pfizer, Merck, Merck/Schering Plough, KOS, AstraZeneca, Abbott, Novo Nordisk, the American Diabetes Association, GlaxoSmith Kline, Novartis, sanofi-aventis, Minimed, and/or Viaject.
Arch Intern Med. 2008;168:1531-1540. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 July 29, 2008 — Colesevelam treatment seems safe and effective for improving glycemic and lipid control in patients with type 2 diabetes receiving insulin therapy, according to the results of a randomized controlled trial reported in the July 28 issue of the Archives of Internal Medicine.
2008.07.29 — 根据《内科学档案》2008年7月号上刊登的一项随机对照实验结果，考来维仑治疗对于接受胰岛素治疗的2型糖尿病患者的血糖和血脂控制安全而有效。
"Poor glycemic control is a risk factor for microvascular complications in patients with type 2 diabetes mellitus," write Ronald B. Goldberg, MD, from the University of Miami in Florida, and colleagues. "Achieving glycemic control safely with insulin therapy can be challenging."
“血糖控制不佳是2型糖尿病患者微血管并发症的一个危险因素，”研究人员之一，来自佛罗里达州迈阿密大学的Ronald B. Goldberg（医学博士）写道，“通过胰岛素治疗安全控制血糖是相当有挑战性的工作。”
Between August 12, 2004, and December 28, 2005, this prospective, 16-week, double-blind, parallel-group study was conducted at 50 sites in the United States and at 1 site in Mexico. Inclusion criteria were type 2 diabetes mellitus inadequately controlled (glycated hemoglobin level, 7.5% - 9.5%) with insulin therapy alone or in combination with oral antidiabetic agents.
从2004.08.12到2005.12.28，这项历时16周的前瞻性双盲平行对照研究在美国50处以及墨西哥一处实验点进行。入选标准为单用胰岛素或联用口服糖尿病药物控制不佳的2型糖尿病患者（糖化血红蛋白水平，7.5%~9.5%）。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-14 00:43
医学,生命科学网